Aurora Cannabis Reports 11% Revenue Growth In Q2, Here’s Why

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) reported its total revenue for the second quarter of 2026, which amounted to $90.4 million, as compared to $81.1 million in the second quarter of last year, representing an 11% year-over-year increase. That’s due to 15% growth in Aurora’s global medical cannabis business and 34% growth in its plant propagation business.

Medical cannabis net revenue was $70.5 million, a 15% increase from the prior-year period, representing 78% of Aurora’s second-quarter 2026 consolidated net revenue.

The increase in medical cannabis net revenue of $9.2 million was primarily due to higher sales to Australia, Germany, Poland, and the UK, as well as increased revenue in Canada to insurance-covered and self-paying patients.

“Aurora’s quarterly performance highlights our continued focus on profitable growth. We achieved record net revenue1 for global medical cannabis, representing a 15% year-over-year increase, while adjusted EBITDA1 rose 52%. These strong results affirm our strategic prioritization of medical cannabis as the industry’s most compelling growth area,” said Executive Chairman and Chief Executive Officer, Miguel Martin.

Other Q2 Financial Highlights

• Adjusted selling, general and administrative expenses were $35.5 million for the quarter, compared to $31.7 million in the prior year period.
• Net loss from continuing operations for the three months ended Sept. 30, 2025 was $53.2 million compared to a net income of $1.4 million for the prior year period.
• Adjusted EBITDA came in positive at $15.4 million for the three months ended September 30, 2025 compared to $10.1 million adjusted EBITDA gain for the prior year period.

ACB Price Action

Aurora’s shares traded 0.88% lower at $4.50 per share at the time of writing on Wednesday.